Company Overview - Beijing Jiukang Biological Technology Co., Ltd. specializes in the research, production, and sales of biochemical diagnostics, blood coagulation testing, blood type testing, and tumor pathology diagnostics [1] - The main products include in vitro diagnostic reagents, in vitro testing instruments, instrument leasing, inspection services, and laboratory auxiliary services [1] Financial Performance - As of the first quarter of 2025, the company reported revenue of 320 million yuan, a year-on-year decrease of 18.81% [1] - The net profit for the same period was 83.26 million yuan, down 30.99% year-on-year, with a gross profit margin of 80.84% [1] Market Position - The company's current stock price is 13.58 yuan, with a rolling price-to-earnings (PE) ratio of 16.13 times [1] - The average PE ratio in the medical device industry is 49.45 times, with a median of 35.92 times, placing Jiukang Biological at the 39th position in the industry ranking [1][2] Shareholder Information - As of March 31, 2025, the number of shareholders is 15,231, a decrease of 547 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Industry Recognition - On February 22, 2023, the company was recognized as a "National Enterprise Technology Center" in the 29th batch of newly identified national enterprise technology centers [1]

北京九强生物技术股份有限公司的主营业务是生化诊断、血凝检测、血型检测和肿瘤病理诊断的研发、 生产和销售。公司的主要产品是体外检测试剂、体外检测仪器、仪器租赁、检验服务、实验辅助业务、 其他业务。2023年2月22日，2022年（第29批）新认定国家企业技术中心名单及全部国家企业技术中心 名单公布，公司成功入选，荣获"国家企业技术中心"认定。 最新一期业绩显示，2025年一季报，公司实现营业收入3.20亿元，同比-18.81%；净利润8325.75万元， 同比-30.99%，销售毛利率80.84%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)39九强生物16.4915.332.0281.66亿行业平均 50.8049.074.67108.36亿行业中值36.7136.842.4850.19亿1天益医疗-1758.71-3012.481.8822.41亿2澳华内 镜-655.90328.975.2569.12亿3诺唯赞-427.65-505.802.3591.52亿4爱朋医疗-397.87302.264.7932.65亿5博晖 创新-335.73532.763.5849.26亿6奥精医疗-136.87 ...

北京九强生物技术股份有限公司的主营业务是生化诊断、血凝检测、血型检测和肿瘤病理诊断的研发、 生产和销售。公司的主要产品是体外检测试剂、体外检测仪器、仪器租赁、检验服务、实验辅助业务、 其他业务。2023年2月22日，2022年（第29批）新认定国家企业技术中心名单及全部国家企业技术中心 名单公布，公司成功入选，荣获"国家企业技术中心"认定。 最新一期业绩显示，2025年一季报，公司实现营业收入3.20亿元，同比-18.81%；净利润8325.75万元， 同比-30.99%，销售毛利率80.84%。 5月20日，九强生物今日收盘13.57元，上涨1.04%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到16.12倍，总市值79.84亿元。 序号股票简称PE(TTM)PE(静)市净率总市值(元)40九强生物16.1214.991.9779.84亿行业平均 49.5147.734.57106.36亿行业中值36.1737.202.5148.58亿1天益医疗-1784.15-3056.061.9022.74亿2澳华内 镜-619.74310.834.9665.31亿3诺唯赞-415.76-491.732 ...